Список проголосовавших за комментарий " Notable movers of interest: EXAS+16.7% on Q4 EPS beat, guidance<p>The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).</p><p><strong>Large Cap Gainers</strong></p><ul><li><strong>TEVA</strong> (37.13 +5.48%): Shares rise after Momenta Pharmaceuticals (<strong>MNTA</strong>) announces that the FDA issued a warning letter to its contracted Glatopa (glatiramer acetate injection) fill/finish manufacturer; Glatopa (glatiramer acetate injection) is the generic candidate of Teva's Copaxone.</li><li><strong>VALE</strong> (11.41 +4.01%): New shareholders' agreement was filed, executed by Litel Participações S.A., Litela Participações S.A., Bradespar S.A., Mitsui & Co., and BNDES Participações.</li><li><strong>EW</strong> (93.3 +3.97%): Shares rise after 10K disclosure that CardiAQ testing has been completed; enrollment has resumed.</li></ul><p><strong>Large Cap Losers</strong></p><ul><li><strong>UL</strong> (44.38 -8.56%): Co and Kraft Heinz (<strong>KHC</strong>) jointly confirm that KHC has amicably agreed to withdraw its proposal for a combination of the two companies.</li><li><strong>FCX</strong> (14.11 -5.4%): Downgraded to Sell from Hold at Deutsche Bank.</li><li><strong>MAR</strong> (88.17 -1.33%): Downgraded to Hold from Buy at SunTrust.</li></ul><p><strong>Mid Cap Gainers</strong></p><ul><li><strong>EXAS</strong> (23.24 +16.73%): Reports Q4 EPS beat; guides FY17 revenues above consensus.</li><li><strong>RBA</strong> (34.16 +10.3%): Reports Q4 EPS and revenue beats.</li><li><strong>TREX</strong> (75.9 +8.72%): Shares rise on Q4 EPS and revenue beats; Q1 revenue guidance slightly above consensus.</li></ul><p><strong>Mid Cap Losers</strong></p><ul><li><strong>WAB</strong> (82.93 -5.51%): Shares fall after reporting Q4 EPS and revenue misses.</li><li><strong>CBRL</strong> (163.12 -3.3%): Reports Q2 revenue miss; guides Q3 EPS below consensus; lowers FY17 revenue guidance. </li></ul>"